Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Black Diamond Therapeutics, Inc. (BDTX)
USD1.81
-0.05 (-2.69%)
US NASDAQ Healthcare Biotechnology
Address
One Main Street 2142
Cambridge, MA, US
Cambridge, MA, US
CEO
Mark A. Velleca
Website
blackdiamondtherapeutics.com
IPO
2020-01-31
CIK 1701541 ISIN US09203E1055
Description
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.81
-0.05 (-2.69%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
3.23
Float Shares
44.98M
Free Float %
78.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.67% | +6.14% | +14.84% | +34.25% | -39.63% | +20.99% | +68.00% | +55.56% | -89.44% | -92.55% | -92.55% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (11 ratings, all time)
Buy
Price Targets & DCF
Current price
1.81
Low
8.00
+342.0%
Consensus
8.00
+342.0%
Median
8.00
+342.0%
High
8.00
+342.0%
DCF (Unlevered)
10.82
+497.6%
DCF (Levered)
6.26
+245.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
89% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 6 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 3 |
8.00
+342.0%
|
| All Time | 8 |
11.88
+556.4%
|
Quality scores
Altman Z-Score
-1.50
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
B-
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%— Q1'26: -100.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+130.7% ★ Q1'26: -116.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+16.4%
-
EBIT margin Biotechnology: +0.0%+28.4% ★
-
ROIC Biotechnology: -16.1%— Q1'26: -51.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+4.6% Q1'26: -0.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.75× ★ Q1'26: -0.31× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 6 EPS Ana. |
Dec 2027 8 Rev. Ana. 6 EPS Ana. |
Dec 2028 8 Rev. Ana. 8 EPS Ana. |
Dec 2029 7 Rev. Ana. 6 EPS Ana. |
Dec 2030 7 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 70.00M (-100.0%)
|
70.00M
est: 70.00M (+0.0%)
|
7.14M
7.14M – 7.14M
-89.8% YoY
|
2.85M
2.85M – 2.85M
-60.2% YoY
|
11.59M
11.59M – 11.59M
+307.3% YoY
|
13.33M
13.33M – 13.33M
+15.0% YoY
|
73.26M
73.26M – 73.26M
+449.8% YoY
|
| EBITDA |
-78.44M
est: 60.04M (-230.6%)
|
20.20M
est: 60.04M (-66.4%)
|
6.13M
6.13M – 6.13M
-89.8% YoY
|
2.44M
2.44M – 2.44M
-60.2% YoY
|
9.94M
9.94M – 9.94M
+307.3% YoY
|
11.43M
11.43M – 11.43M
+15.0% YoY
|
62.84M
62.84M – 62.84M
+449.8% YoY
|
| EBIT |
-78.78M
est: 59.97M (-231.4%)
|
19.87M
est: 59.97M (-66.9%)
|
6.12M
6.12M – 6.12M
-89.8% YoY
|
2.44M
2.44M – 2.44M
-60.2% YoY
|
9.93M
9.93M – 9.93M
+307.3% YoY
|
11.42M
11.42M – 11.42M
+15.0% YoY
|
62.77M
62.77M – 62.77M
+449.8% YoY
|
| Net Income |
-69.68M
est: -74.22M (+6.1%)
|
22.37M
est: 27.85M (-19.7%)
|
-40.48M
-49.21M – -6.47M
-245.3% YoY
|
-66.80M
-107.44M – -26.42M
-65.0% YoY
|
-88.37M
-90.79M – -33.12M
-32.3% YoY
|
-68.50M
-68.50M – -68.50M
+22.5% YoY
|
-38.66M
-38.66M – -38.66M
+43.6% YoY
|
| SGA |
27.47M
est: 59.31M (-53.7%)
|
16.57M
est: 59.31M (-72.1%)
|
6.05M
6.05M – 6.05M
-89.8% YoY
|
2.41M
2.41M – 2.41M
-60.2% YoY
|
9.82M
9.82M – 9.82M
+307.3% YoY
|
11.29M
11.29M – 11.29M
+15.0% YoY
|
62.08M
62.08M – 62.08M
+449.8% YoY
|
| EPS |
-1.27
est: -1.30 (+2.3%)
|
0.39
est: 0.45 (-12.7%)
|
-0.64
-0.85 – -0.11
-243.5% YoY
|
-0.96
-1.87 – -0.46
-49.5% YoY
|
-0.93
-1.58 – -0.58
+3.1% YoY
|
-1.19
-1.19 – -1.19
-28.1% YoY
|
-0.67
-0.67 – -0.67
+43.6% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-29 | BTIG | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-05 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-04 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-01 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-30 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-29 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-28 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-27 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-24 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-23 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-131.33M
OE per share TTM
-2.29
Owner's Yield
-76.74%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
173.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
19
Total invested
5.45M
Insider transactions (90d)
0
Beneficial owners (>5%)
43
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | GP-GP, | 7.47M | 20.80% | — | 7.47M | — | 7.47M | OO | — | 2020-02-13 | ↗ |
| 2 | Versant Ventures VI GP, L.P. | 7.47M | 20.80% | — | 7.47M | — | 7.47M | OO | — | 2020-02-13 | ↗ |
| 3 | Versant Venture Capital VI, L.P. | 6.81M | 19.00% | 6.81M | — | 6.81M | — | PN | — | 2020-02-13 | ↗ |
| 4 | Ryan Wilder | 5.03M | 8.90% | — | 5.03M | — | — | HC, IN | Delaware | 2024-11-14 | ↗ |
| 5 | Vestal Point Capital, LP | 5.03M | 8.90% | — | 5.03M | — | — | IA, PN | Delaware | 2024-11-14 | ↗ |
| 6 | BB Biotech AG | 3.99M | 11.00% | — | 3.99M | — | 3.99M | HC, CO | Switzerland | 2022-04-14 | ↗ |
| 7 | Biotech Growth N.V. | 3.99M | 11.00% | — | 3.99M | — | 3.99M | CO | Switzerland | 2022-04-14 | ↗ |
| 8 | 85-4328500 | 3.93M | 7.60% | 1.53M | — | 3.93M | — | IA | Maryland | 2024-02-14 | ↗ |
| 9 | (1) BlackRock, Inc. | 3.50M | 6.20% | — | — | 3.50M | — | HC | Delaware | 2024-11-08 | ↗ |
| 10 | Ali Behbahani | 3.45M | 9.60% | — | 3.45M | — | 3.45M | IN | — | 2020-02-13 | ↗ |
| 11 | Anthony A. Florence, Jr. | 3.45M | 9.60% | — | 3.45M | — | 3.45M | IN | — | 2020-02-13 | ↗ |
| 12 | Carmen Chang | 3.45M | 9.60% | — | 3.45M | — | 3.45M | IN | — | 2020-02-13 | ↗ |
| 13 | Forest Baskett | 3.45M | 9.60% | — | 3.45M | — | 3.45M | IN | — | 2020-02-13 | ↗ |
| 14 | Joshua Makower | 3.45M | 9.60% | — | 3.45M | — | 3.45M | IN | — | 2020-02-13 | ↗ |
| 15 | Mohamad H. Makhzoumi | 3.45M | 9.60% | — | 3.45M | — | 3.45M | IN | — | 2020-02-13 | ↗ |
| 16 | NEA 16 GP, LLC | 3.45M | 9.60% | — | 3.45M | — | 3.45M | OO | — | 2020-02-13 | ↗ |
| 17 | NEA Partners 16, L.P. | 3.45M | 9.60% | — | 3.45M | — | 3.45M | PN | — | 2020-02-13 | ↗ |
| 18 | New Enterprise Associates 16, L.P. | 3.45M | 9.60% | — | 3.45M | — | 3.45M | PN | — | 2020-02-13 | ↗ |
| 19 | Paul Walker | 3.45M | 9.60% | — | 3.45M | — | 3.45M | IN | — | 2020-02-13 | ↗ |
| 20 | Peter W. Sonsini | 3.45M | 9.60% | — | 3.45M | — | 3.45M | IN | — | 2020-02-13 | ↗ |
| 21 | Scott D. Sandell | 3.45M | 9.60% | — | 3.45M | — | 3.45M | IN | — | 2020-02-13 | ↗ |
| 22 | 10. | 3.44M | 9.50% | — | 3.44M | — | 3.44M | HC, CO | — | 2022-02-11 | ↗ |
| 23 | 2. | 3.44M | 9.50% | — | 3.44M | — | 3.44M | CO | — | 2022-02-11 | ↗ |
| 24 | Peter Kolchinsky | 2.59M | 7.20% | — | 2.59M | — | 10.00 | HC, IN | States | 2020-02-05 | ↗ |
| 25 | RA Capital Management, L.P. | 2.59M | 7.20% | — | 2.59M | — | 10.00 | IA, PN | Citizenship or Place of Organization. Delaware | 2020-02-05 | ↗ |
| 26 | Rajeev Shah | 2.59M | 7.20% | — | 2.59M | — | 10.00 | HC, IN | States | 2020-02-05 | ↗ |
| 27 | Versant Voyageurs I GP Company | 2.21M | 6.20% | — | 2.21M | — | 2.21M | OO | — | 2020-02-13 | ↗ |
| 28 | Versant Voyageurs I, L.P. | 2.21M | 6.20% | 2.21M | — | 2.21M | — | PN | — | 2020-02-13 | ↗ |
| 29 | Boxer Asset Management Inc. | 2.01M | 5.60% | — | 2.01M | — | 2.01M | CO | Bahamas | 2020-02-13 | ↗ |
| 30 | Boxer Capital, LLC | 2.01M | 5.60% | — | 2.01M | — | 2.01M | OO | Delaware | 2020-02-13 | ↗ |
| 31 | Joe Lewis | 2.01M | 5.60% | — | 2.01M | — | 2.01M | IN | Kingdom | 2020-02-13 | ↗ |
| 32 | The Vanguard Group - 23-1945930 | 1.85M | 5.13% | — | 38.6K | 1.80M | 48.8K | IA | Pennsylvania | 2021-02-10 | ↗ |
| 33 | Versant Vantage I GP, L.P. | 1.21M | 3.40% | — | 1.21M | — | 1.21M | OO | — | 2020-02-13 | ↗ |
| 34 | Versant Vantage I GP-GP, LLC | 1.21M | 3.40% | — | 1.21M | — | 1.21M | OO | — | 2020-02-13 | ↗ |
| 35 | Versant Vantage I, L.P. | 1.21M | 3.40% | 1.21M | — | 1.21M | — | PN | — | 2020-02-13 | ↗ |
| 36 | Deerfield Management Company, L.P. | 778.8K | 2.27% | — | 778.8K | — | — | PN | Delaware | 2020-02-03 | ↗ |
| 37 | Deerfield Mgmt, L.P. | 778.8K | 2.27% | — | 778.8K | — | — | PN | Delaware | 2020-02-03 | ↗ |
| 38 | Deerfield Partners, L.P. | 778.8K | 2.27% | — | 778.8K | — | — | PN | Delaware | 2020-02-03 | ↗ |
| 39 | James E. Flynn | 778.8K | 2.27% | — | 778.8K | — | — | IN | United States | 2020-02-03 | ↗ |
| 40 | Versant Voyageurs I GP, L.P. | 658.9K | 1.80% | — | 658.9K | — | 658.9K | OO | — | 2020-02-13 | ↗ |
| 41 | Versant Voyageurs I Parallel, L.P. | 658.9K | 1.80% | 658.9K | — | 658.9K | — | PN | — | 2020-02-13 | ↗ |
| 42 | 10 | 60.9K | 0.20% | — | 60.9K | — | 60.9K | IN | — | 2020-02-13 | ↗ |
| 43 | MVA Investors, LLC | 60.9K | 0.20% | — | 60.9K | — | 60.9K | OO | Delaware | 2020-02-13 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
19
-91 vs prev Q
New positions
2
Closed positions
87
Increased
8
Reduced
6
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | NVERSES CAPITAL, LLC | 10.7K +10.7K (+100.0%) | 26.05M +26.1M (+100.0%) | 0.02% +0.019 pp | 0.06% +0.058 pp | USD2.43 +0.0% | 1 qtrs NEW |
| 2 | T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 10.61M -137.5K (-1.3%) | 25.78M -14.9M (-36.7%) | 18.72% -0.193 pp | 0.02% -0.009 pp | USD4.05 -40.0% | 10 qtrs — |
| 3 | NEA MANAGEMENT COMPANY, LLC | 4.45M +— (+0.0%) | 10.81M -6.1M (-35.9%) | 7.85% +0.021 pp | 0.55% -0.374 pp | USD20.48 -88.1% | 24 qtrs — |
| 4 | VANGUARD GROUP INC | 2.19M +— (+0.0%) | 5.32M -3.0M (-35.9%) | 3.86% +0.010 pp | 0.00% +0.000 pp | USD10.65 -77.2% | 24 qtrs — |
| 5 | ACADIAN ASSET MANAGEMENT LLC | 1.63M +1.1M (+238.8%) | 3.96M +2.1M (+117.4%) | 2.88% +2.030 pp | 0.01% +0.003 pp | USD2.83 -14.1% | 5 qtrs — |
| 6 | MARSHALL WACE, LLP | 1.11M -189.1K (-14.6%) | 2.70M -2.2M (-45.2%) | 1.96% -0.328 pp | 0.00% -0.003 pp | USD3.05 -20.3% | 3 qtrs — |
| 7 | SIREN, L.L.C. | 1.05M +— (+0.0%) | 2.54M -1.4M (-35.9%) | 1.85% +0.005 pp | 0.08% -0.079 pp | USD4.35 -44.1% | 6 qtrs — |
| 8 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.04M +143.6K (+16.0%) | 2.53M -870.7K (-25.6%) | 1.84% +0.258 pp | 0.00% -0.001 pp | USD3.43 -29.2% | 3 qtrs — |
| 9 | JANE STREET GROUP, LLC | 961.8K +724.5K (+305.3%) | 2.34M +1.4M (+159.9%) | 1.70% +1.280 pp | 0.00% +0.000 pp | USD2.48 -2.0% | 3 qtrs — |
| 10 | RENAISSANCE TECHNOLOGIES LLC | 949.7K +350.3K (+58.4%) | 2.31M +36.1K (+1.6%) | 1.68% +0.621 pp | 0.00% +0.001 pp | USD3.08 -21.1% | 17 qtrs — |
| 11 | BLACKROCK, INC. | 888.3K -139.8K (-13.6%) | 2.16M -1.7M (-44.6%) | 1.57% -0.242 pp | 0.00% +0.000 pp | USD4.34 -44.0% | 6 qtrs — |
| 12 | VESTAL POINT CAPITAL, LP | 870.0K -4.7M (-84.3%) | 2.11M -18.9M (-89.9%) | 1.54% -8.235 pp | 0.07% -0.878 pp | USD4.26 -43.0% | 7 qtrs — |
| 13 | DIMENSIONAL FUND ADVISORS LP | 857.0K +401.1K (+88.0%) | 2.08M +355.4K (+20.6%) | 1.51% +0.710 pp | 0.00% +0.000 pp | USD2.61 -6.9% | 14 qtrs — |
| 14 | D. E. SHAW & CO., INC. | 655.8K +512.1K (+356.5%) | 1.59M +1.0M (+192.7%) | 1.16% +0.905 pp | 0.00% +0.001 pp | USD2.68 -9.3% | 5 qtrs — |
| 15 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 654.7K +523.1K (+397.4%) | 1.59M +1.1M (+218.9%) | 1.16% +0.924 pp | 0.00% +0.003 pp | USD2.70 -10.0% | 2 qtrs — |
| 16 | AWM INVESTMENT COMPANY, INC. | 625.0K +25.0K (+4.2%) | 1.52M -755.3K (-33.2%) | 1.10% +0.047 pp | 0.15% -0.067 pp | USD1.94 +25.3% | 4 qtrs — |
| 17 | FMR LLC | 541.2K +87.6K (+19.3%) | 1.32M -404.0K (-23.5%) | 0.96% +0.157 pp | 0.00% +0.000 pp | USD2.93 -17.1% | 6 qtrs — |
| 18 | GEODE CAPITAL MANAGEMENT, LLC | 505.8K +5.3K (+1.1%) | 1.23M -668.2K (-35.2%) | 0.89% +0.012 pp | 0.00% +0.000 pp | USD9.16 -73.5% | 24 qtrs — |
| 19 | NORTHERN TRUST CORP | 472.7K -15.4K (-3.1%) | 1.15M -701.1K (-37.9%) | 0.83% -0.025 pp | 0.00% 0.000 pp | USD4.46 -45.5% | 24 qtrs — |
| 20 | CITADEL ADVISORS LLC | 425.5K +425.5K (+100.0%) | 1.03M +1.0M (+100.0%) | 0.75% +0.751 pp | 0.00% +0.000 pp | USD2.43 +0.0% | 3 qtrs — |
| 21 | WINTON GROUP LTD | 421.3K +421.3K (+100.0%) | 1.02M +1.0M (+100.0%) | 0.74% +0.744 pp | 0.04% +0.035 pp | USD2.43 +0.0% | 1 qtrs NEW |
| 22 | MACKENZIE FINANCIAL CORP | 352.5K +352.5K (+100.0%) | 875.9K +875.9K (+100.0%) | 0.62% +0.622 pp | 0.00% +0.001 pp | USD2.43 +0.0% | 1 qtrs NEW |
| 23 | O'SHAUGHNESSY ASSET MANAGEMENT, LLC | 354.5K +212.0K (+148.8%) | 861.3K +321.5K (+59.6%) | 0.63% +0.375 pp | 0.00% +0.002 pp | USD2.98 -18.5% | 2 qtrs — |
| 24 | GOLDMAN SACHS GROUP INC | 325.3K -123.7K (-27.5%) | 790.5K -911.2K (-53.5%) | 0.57% -0.216 pp | 0.00% 0.000 pp | USD3.53 -31.2% | 9 qtrs — |
| 25 | GLOBEFLEX CAPITAL L P | 305.3K +— (+0.0%) | 741.8K -415.2K (-35.9%) | 0.54% +0.001 pp | 0.11% -0.065 pp | USD3.79 -35.9% | 2 qtrs — |
| 26 | MILLENNIUM MANAGEMENT LLC | 296.6K -553.8K (-65.1%) | 720.6K -2.5M (-77.6%) | 0.52% -0.974 pp | 0.00% -0.001 pp | USD2.33 +4.3% | 24 qtrs — |
| 27 | STIFEL FINANCIAL CORP | 275.0K +52.8K (+23.7%) | 668.2K -174.1K (-20.7%) | 0.49% +0.094 pp | 0.00% 0.000 pp | USD2.80 -13.2% | 10 qtrs — |
| 28 | J. GOLDMAN & CO LP | 270.0K +270.0K (+100.0%) | 656.1K +656.1K (+100.0%) | 0.48% +0.477 pp | 0.02% +0.017 pp | USD2.43 +0.0% | 4 qtrs — |
| 29 | UBS GROUP AG | 257.6K -370.8K (-59.0%) | 626.0K -1.8M (-73.7%) | 0.45% -0.652 pp | 0.00% 0.000 pp | USD3.13 -22.4% | 24 qtrs — |
| 30 | 683 CAPITAL MANAGEMENT, LLC | 248.0K +248.0K (+100.0%) | 602.5K +602.5K (+100.0%) | 0.44% +0.438 pp | 0.03% +0.026 pp | USD2.43 +0.0% | 1 qtrs NEW |
| 31 | GSA CAPITAL PARTNERS LLP | 245.7K +123.0K (+100.2%) | 597.0K +132.0K (+28.4%) | 0.43% +0.218 pp | 0.05% +0.013 pp | USD2.45 -0.8% | 3 qtrs — |
| 32 | RITHOLTZ WEALTH MANAGEMENT | 227.9K +126.4K (+124.5%) | 553.7K +169.1K (+44.0%) | 0.40% +0.224 pp | 0.01% +0.003 pp | USD3.04 -20.1% | 2 qtrs — |
| 33 | BANK OF NEW YORK MELLON CORP | 214.7K +89.0K (+70.8%) | 521.7K +45.4K (+9.5%) | 0.38% +0.158 pp | 0.00% +0.000 pp | USD3.25 -25.2% | 7 qtrs — |
| 34 | STATE STREET CORP | 213.5K +— (+0.0%) | 518.8K -290.4K (-35.9%) | 0.38% +0.001 pp | 0.00% +0.000 pp | USD6.14 -60.4% | 24 qtrs — |
| 35 | CANADA PENSION PLAN INVESTMENT BOARD | 203.1K +203.1K (+100.0%) | 493.5K +493.5K (+100.0%) | 0.36% +0.359 pp | 0.00% +0.000 pp | USD2.43 +0.0% | 1 qtrs NEW |
| 36 | POINT72 ASSET MANAGEMENT, L.P. | 196.7K +196.7K (+100.0%) | 478.1K +478.1K (+100.0%) | 0.35% +0.347 pp | 0.00% +0.001 pp | USD2.43 +0.0% | 1 qtrs NEW |
| 37 | TD ASSET MANAGEMENT INC | 195.9K +12.5K (+6.8%) | 476.1K -219.1K (-31.5%) | 0.35% +0.023 pp | 0.00% 0.000 pp | USD4.52 -46.2% | 8 qtrs — |
| 38 | DIADEMA PARTNERS LP | 190.4K +190.4K (+100.0%) | 462.7K +462.7K (+100.0%) | 0.34% +0.336 pp | 0.08% +0.080 pp | USD2.43 +0.0% | 1 qtrs NEW |
| 39 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 173.3K +75.0K (+76.3%) | 421.1K +48.6K (+13.0%) | 0.31% +0.133 pp | 0.01% +0.001 pp | USD2.51 -3.2% | 16 qtrs — |
| 40 | QUBE RESEARCH & TECHNOLOGIES LTD | 169.6K +91.4K (+116.7%) | 412.2K +115.5K (+39.0%) | 0.30% +0.162 pp | 0.00% +0.000 pp | USD2.49 -2.4% | 11 qtrs — |
| 41 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 159.0K -52.1K (-24.7%) | 386.3K -413.7K (-51.7%) | 0.28% -0.091 pp | 0.01% -0.007 pp | USD3.44 -29.4% | 3 qtrs — |
| 42 | OMERS ADMINISTRATION CORP | 138.9K +127.9K (+1,162.7%) | 337.5K +295.8K (+709.6%) | 0.25% +0.226 pp | 0.00% +0.002 pp | USD2.54 -4.3% | 2 qtrs — |
| 43 | KENNEDY CAPITAL MANAGEMENT LLC | 133.1K +3.2K (+2.4%) | 323.5K -169.0K (-34.3%) | 0.24% +0.006 pp | 0.01% -0.004 pp | USD4.34 -44.0% | 11 qtrs — |
| 44 | INVESCO LTD. | 131.4K +36.1K (+37.9%) | 319.4K -42.0K (-11.6%) | 0.23% +0.064 pp | 0.00% +0.000 pp | USD2.91 -16.5% | 7 qtrs — |
| 45 | MAN GROUP PLC | 130.0K +51.7K (+66.0%) | 316.0K +19.1K (+6.4%) | 0.23% +0.092 pp | 0.00% +0.000 pp | USD2.83 -14.1% | 3 qtrs — |
| 46 | XTX TOPCO LTD | 119.7K -96.5K (-44.6%) | 290.8K -528.6K (-64.5%) | 0.21% -0.169 pp | 0.01% -0.035 pp | USD2.64 -8.0% | 5 qtrs — |
| 47 | OXFORD ASSET MANAGEMENT LLP | 114.4K +114.4K (+100.0%) | 278.0K +278.0K (+100.0%) | 0.20% +0.202 pp | 0.11% +0.113 pp | USD2.43 +0.0% | 1 qtrs NEW |
| 48 | AMERICAN CENTURY COMPANIES INC | 108.1K +15.7K (+17.0%) | 262.7K -87.6K (-25.0%) | 0.19% +0.028 pp | 0.00% +0.000 pp | USD3.45 -29.6% | 3 qtrs — |
| 49 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 104.7K +104.7K (+100.0%) | 254.5K +254.5K (+100.0%) | 0.18% +0.185 pp | 0.00% +0.000 pp | USD2.43 +0.0% | 21 qtrs — |
| 50 | VERDAD ADVISERS, LP | 96.3K +96.3K (+100.0%) | 234.0K +234.0K (+100.0%) | 0.17% +0.170 pp | 0.27% +0.268 pp | USD2.43 +0.0% | 1 qtrs NEW |
| 51 | MORGAN STANLEY | 95.1K +26.0K (+37.6%) | 231.2K -30.8K (-11.8%) | 0.17% +0.046 pp | 0.00% +0.000 pp | USD2.62 -7.3% | 24 qtrs — |
| 52 | GRAHAM CAPITAL MANAGEMENT, L.P. | 86.6K +50.0K (+137.0%) | 210.3K +71.9K (+52.0%) | 0.15% +0.089 pp | 0.01% +0.003 pp | USD2.45 -0.8% | 3 qtrs — |
| 53 | ROUND ROCK ADVISORS, LLC | 79.5K +79.5K (+100.0%) | 193.3K +193.3K (+100.0%) | 0.14% +0.140 pp | 0.03% +0.029 pp | USD2.43 +0.0% | 1 qtrs NEW |
| 54 | BARCLAYS PLC | 74.8K -3.3K (-4.3%) | 181.8K -158.2K (-46.5%) | 0.13% -0.006 pp | 0.00% +0.000 pp | USD3.83 -36.6% | 16 qtrs — |
| 55 | STATE OF WYOMING | 70.3K +46.1K (+189.6%) | 170.9K +78.9K (+85.7%) | 0.12% +0.081 pp | 0.02% +0.008 pp | USD2.90 -16.2% | 2 qtrs — |
| 56 | HILLSDALE INVESTMENT MANAGEMENT INC. | 63.6K +— (+0.0%) | 154.6K -86.5K (-35.9%) | 0.11% +0.000 pp | 0.00% -0.003 pp | USD3.79 -35.9% | 2 qtrs — |
| 57 | ALPHACENTRIC ADVISORS LLC | 53.6K +53.6K (+100.0%) | 130.3K +130.3K (+100.0%) | 0.09% +0.095 pp | 0.13% +0.130 pp | USD2.43 +0.0% | 1 qtrs NEW |
| 58 | BANK OF AMERICA CORP /DE/ | 51.1K +7.7K (+17.9%) | 124.2K -40.2K (-24.4%) | 0.09% +0.014 pp | 0.00% +0.000 pp | USD3.17 -23.3% | 24 qtrs — |
| 59 | TWO SIGMA SECURITIES, LLC | 40.5K +25.9K (+177.4%) | 98.5K +43.1K (+77.8%) | 0.07% +0.046 pp | 0.01% +0.005 pp | USD2.50 -2.8% | 3 qtrs — |
| 60 | JUMP FINANCIAL, LLC | 39.0K +39.0K (+100.0%) | 94.8K +94.8K (+100.0%) | 0.07% +0.069 pp | 0.00% +0.001 pp | USD2.43 +0.0% | 3 qtrs — |
| 61 | LPL FINANCIAL LLC | 37.0K -32.3K (-46.6%) | 89.9K -172.5K (-65.7%) | 0.07% -0.057 pp | 0.00% 0.000 pp | USD1.58 +53.8% | 4 qtrs — |
| 62 | RB CAPITAL MANAGEMENT, LLC | 35.0K +35.0K (+100.0%) | 85.1K +85.1K (+100.0%) | 0.06% +0.062 pp | 0.02% +0.017 pp | USD2.43 +0.0% | 1 qtrs NEW |
| 63 | KATHMERE CAPITAL MANAGEMENT, LLC | 31.8K +7.5K (+31.0%) | 77.3K -14.7K (-16.0%) | 0.06% +0.013 pp | 0.01% -0.001 pp | USD3.47 -30.0% | 2 qtrs — |
| 64 | LIGHTHOUSE INVESTMENT PARTNERS, LLC | 31.2K +31.2K (+100.0%) | 75.8K +75.8K (+100.0%) | 0.06% +0.055 pp | 0.00% +0.002 pp | USD2.43 +0.0% | 1 qtrs NEW |
| 65 | TWO SIGMA ADVISERS, LP | 28.6K +14.6K (+104.3%) | 69.5K +16.4K (+31.0%) | 0.05% +0.026 pp | 0.00% +0.000 pp | USD3.10 -21.6% | 2 qtrs — |
| 66 | HSBC HOLDINGS PLC | 26.4K +— (+0.0%) | 66.8K -30.9K (-31.6%) | 0.05% +0.000 pp | 0.00% +0.000 pp | USD2.98 -18.5% | 6 qtrs — |
| 67 | HCR WEALTH ADVISORS | 27.0K +27.0K (+100.0%) | 65.6K +65.6K (+100.0%) | 0.05% +0.048 pp | 0.01% +0.007 pp | USD2.43 +0.0% | 1 qtrs NEW |
| 68 | HRT FINANCIAL LP | 26.4K +26.4K (+100.0%) | 64.0K +64.0K (+100.0%) | 0.05% +0.047 pp | 0.00% +0.000 pp | USD2.43 +0.0% | 1 qtrs NEW |
| 69 | CITIGROUP INC | 24.0K +23.1K (+2,538.2%) | 58.4K +55.0K (+1,591.4%) | 0.04% +0.041 pp | 0.00% +0.000 pp | USD2.49 -2.4% | 10 qtrs — |
| 70 | JEFFERIES FINANCIAL GROUP INC. | 21.7K -1.1K (-5.0%) | 52.6K -33.8K (-39.1%) | 0.04% -0.002 pp | 0.00% 0.000 pp | USD3.79 -35.9% | 2 qtrs — |
| 71 | ENGINEERS GATE MANAGER LP | 19.7K +6.5K (+48.9%) | 47.9K -2.3K (-4.5%) | 0.03% +0.012 pp | 0.00% +0.000 pp | USD2.46 -1.2% | 7 qtrs — |
| 72 | DLK INVESTMENT MANAGEMENT, LLC | 18.2K -2.0K (-9.9%) | 44.2K -32.3K (-42.2%) | 0.03% -0.003 pp | 0.02% -0.012 pp | USD2.74 -11.3% | 9 qtrs — |
| 73 | BEACON CAPITAL MANAGEMENT, LLC | 15.6K +— (+0.0%) | 37.9K -21.2K (-35.9%) | 0.03% +0.000 pp | 0.01% -0.003 pp | USD2.42 +0.4% | 16 qtrs — |
| 74 | ETHIC INC. | 15.4K -144.0 (-0.9%) | 37.5K -21.6K (-36.5%) | 0.03% 0.000 pp | 0.00% 0.000 pp | USD3.79 -35.9% | 2 qtrs — |
| 75 | SQUAREPOINT OPS LLC | 14.8K -2.4K (-14.1%) | 35.8K -29.3K (-44.9%) | 0.03% -0.004 pp | 0.00% +0.000 pp | USD2.59 -6.2% | 9 qtrs — |
| 76 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 14.5K +— (+0.0%) | 35.2K -19.7K (-35.9%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD4.72 -48.5% | 11 qtrs — |
| 77 | RAYMOND JAMES FINANCIAL INC | 13.5K -3.7K (-21.8%) | 32.7K -32.5K (-49.8%) | 0.02% -0.007 pp | 0.00% +0.000 pp | USD2.04 +19.1% | 5 qtrs — |
| 78 | PRUDENTIAL FINANCIAL INC | 12.9K -250.0 (-1.9%) | 31.2K -18.4K (-37.1%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD2.48 -2.0% | 3 qtrs — |
| 79 | SHERBROOKE PARK ADVISERS LLC | 12.1K +12.1K (+100.0%) | 29.3K +29.3K (+100.0%) | 0.02% +0.021 pp | 0.08% +0.076 pp | USD2.43 +0.0% | 1 qtrs NEW |
| 80 | STOKES FAMILY OFFICE, LLC | 11.1K +11.1K (+100.0%) | 26.9K +26.9K (+100.0%) | 0.02% +0.020 pp | 0.00% +0.003 pp | USD2.43 +0.0% | 1 qtrs NEW |
| 81 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 9.3K +9.3K (+100.0%) | 22.6K +22.6K (+100.0%) | 0.02% +0.016 pp | 0.00% +0.002 pp | USD2.43 +0.0% | 1 qtrs NEW |
| 82 | TOWER RESEARCH CAPITAL LLC (TRC) | 8.4K +8.4K (+100.0%) | 20.4K +20.4K (+100.0%) | 0.01% +0.015 pp | 0.00% +0.001 pp | USD2.43 +0.0% | 23 qtrs — |
| 83 | LOS ANGELES CAPITAL MANAGEMENT LLC | 4.7K +4.7K (+100.0%) | 18.0K +18.0K (+100.0%) | 0.01% +0.008 pp | 0.00% +0.000 pp | USD2.43 +0.0% | 1 qtrs NEW |
| 84 | JPMORGAN CHASE & CO | 7.0K +6.7K (+2,217.5%) | 17.0K +15.9K (+1,385.4%) | 0.01% +0.012 pp | 0.00% +0.000 pp | USD2.49 -2.4% | 24 qtrs — |
| 85 | FEDERATED HERMES, INC. | 5.0K -187.0 (-3.6%) | 12.1K -7.5K (-38.2%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD3.72 -34.7% | 3 qtrs — |
| 86 | MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 2.8K +2.8K (+100.0%) | 6.7K +6.7K (+100.0%) | 0.00% +0.005 pp | 0.00% +0.000 pp | USD2.43 +0.0% | 1 qtrs NEW |
| 87 | BNP PARIBAS ARBITRAGE, SNC | 2.6K +2.5K (+1,504.3%) | 6.4K +5.8K (+927.8%) | 0.00% +0.004 pp | 0.00% +0.000 pp | USD2.41 +0.8% | 5 qtrs — |
| 88 | WEBSTER BANK, N. A. | 2.0K -4.0K (-66.7%) | 4.9K -17.9K (-78.6%) | 0.00% -0.007 pp | 0.00% -0.002 pp | USD3.79 -35.9% | 2 qtrs — |
| 89 | GROUP ONE TRADING, L.P. | 1.6K -2.8K (-63.1%) | 3.9K -12.7K (-76.3%) | 0.00% -0.005 pp | 0.00% +0.000 pp | USD3.79 -35.9% | 9 qtrs — |
| 90 | GF FUND MANAGEMENT CO. LTD. | 1.1K +1.1K (+100.0%) | 2.7K +2.7K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD2.43 +0.0% | 1 qtrs NEW |
| 91 | US BANCORP \DE\ | 1.0K +1.0K (+100.0%) | 2.4K +2.4K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD2.43 +0.0% | 1 qtrs NEW |
| 92 | NISA INVESTMENT ADVISORS, LLC | 892.00 +— (+0.0%) | 2.2K -1.2K (-35.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.48 -2.0% | 6 qtrs — |
| 93 | ADVISOR GROUP HOLDINGS, INC. | 860.00 -84.0 (-8.9%) | 2.1K -669.0 (-24.2%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD3.48 -30.2% | 20 qtrs — |
| 94 | ROYAL BANK OF CANADA | 992.00 +992.0 (+100.0%) | 2.0K +2.0K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD2.43 +0.0% | 11 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 52 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree U.S. SmallCap Fund EES | 0.04% | 262.6K | 0.38% |
| 2 | iShares Micro-Cap ETF IWC | 0.02% | 304.6K | 0.60% |
| 3 | EA Bridgeway Omni Small-Cap Value ETF BSVO | 0.02% | 344.4K | 0.47% |
| 4 | iShares U.S. Small-Cap Equity Factor ETF SMLF | 0.02% | 708.6K | 0.15% |
| 5 | Fidelity Enhanced Small Cap ETF FESM | 0.02% | 924.8K | 0.28% |
| 6 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.01% | 35.0K | 0.40% |
| 7 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.01% | 5.6K | 0.19% |
| 8 | iShares Biotechnology ETF IBB | 0.01% | 675.4K | 0.44% |
| 9 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.01% | 5.2K | 0.35% |
| 10 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.01% | 77.1K | 0.35% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
7
Sells
0
Shares acquired
1.56M
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+1,563,024
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-20 | Raman Prakash | Director | A-Award | A | Common Stock | 6,105 | 2.15 | 13.1K | 37,132 | D | ↗ |
| 2026-03-20 | Behbahani Ali | Director | A-Award | A | Common Stock | 6,919 | 2.15 | 14.9K | 93,568 | D | ↗ |
| 2026-01-21 | Yurasov Sergey | Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 2.57 | 642.5K | 250,000 | D | ↗ |
| 2026-01-21 | Velleca Mark A. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 600,000 | 2.57 | 1.54M | 600,000 | D | ↗ |
| 2026-01-21 | Jones Erika | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 2.57 | 514.0K | 200,000 | D | ↗ |
| 2026-01-21 | Hatzis-Schoch Brent | Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 2.57 | 642.5K | 250,000 | D | ↗ |
| 2026-01-21 | Buck Elizabeth | Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 2.57 | 642.5K | 250,000 | D | ↗ |
| 2025-12-12 | Raman Prakash | Director | A-Award | A | Common Stock | 4,665 | 2.76 | 12.9K | 31,027 | D | ↗ |
| 2025-12-12 | Behbahani Ali | Director | A-Award | A | Common Stock | 5,208 | 2.76 | 14.4K | 86,649 | D | ↗ |
| 2025-09-19 | Raman Prakash | Director | A-Award | A | Common Stock | 3,843 | 3.35 | 12.9K | 26,362 | D | ↗ |
| 2025-09-19 | Behbahani Ali | Director | A-Award | A | Common Stock | 4,291 | 3.35 | 14.4K | 81,441 | D | ↗ |
| 2025-06-20 | Raman Prakash | Director | A-Award | A | Common Stock | 5,526 | 2.33 | 12.9K | 22,519 | D | ↗ |
| 2025-06-20 | Behbahani Ali | Director | A-Award | A | Common Stock | 6,170 | 2.33 | 14.4K | 77,150 | D | ↗ |
| 2025-06-12 | Raman Prakash | Director | A-Award | A | Stock Option (Right to Buy) | 30,550 | 2.43 | 74.2K | 30,550 | D | ↗ |
| 2025-06-12 | Menzel Garry E | Director | A-Award | A | Stock Option (Right to Buy) | 30,550 | 2.43 | 74.2K | 30,550 | D | ↗ |
| 2025-06-12 | Kulkarni Samarth | Director | A-Award | A | Stock Option (Right to Buy) | 30,550 | 2.43 | 74.2K | 30,550 | D | ↗ |
| 2025-06-12 | Dhingra Kapil | Director | A-Award | A | Stock Option (Right to Buy) | 30,550 | 2.43 | 74.2K | 30,550 | D | ↗ |
| 2025-06-12 | Campbell Shannon | Director | A-Award | A | Stock Option (Right to Buy) | 30,550 | 2.43 | 74.2K | 30,550 | D | ↗ |
| 2025-06-12 | Behbahani Ali | Director | A-Award | A | Stock Option (Right to Buy) | 30,550 | 2.43 | 74.2K | 30,550 | D | ↗ |
| 2025-03-21 | Raman Prakash | Director | A-Award | A | Common Stock | 6,848 | 1.88 | 12.9K | 16,993 | D | ↗ |
| 2025-03-21 | Behbahani Ali | Director | A-Award | A | Common Stock | 7,646 | 1.88 | 14.4K | 70,980 | D | ↗ |
| 2025-03-19 | BIOTECH GROWTH N V | 10% Owner | S-Sale | D | Common Stock | 2,000,000 | 2.00 | 4.00M | 4,217,839 | D | ↗ |
| 2025-01-30 | Yurasov Sergey | Officer | A-Award | A | Common Stock | 75,000 | 0.00 | — | 75,000 | D | ↗ |
| 2025-01-30 | Velleca Mark A. | Director / Officer | A-Award | A | Common Stock | 75,000 | 0.00 | — | 121,522 | D | ↗ |
| 2025-01-30 | Jones Erika | Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 2.52 | 315.0K | 125,000 | D | ↗ |
| 2025-01-30 | Hatzis-Schoch Brent | Officer | A-Award | A | Common Stock | 75,000 | 0.00 | — | 83,400 | D | ↗ |
| 2025-01-30 | Buck Elizabeth | Officer | A-Award | A | Stock Option (Right to Buy) | 175,000 | 2.52 | 441.0K | 175,000 | D | ↗ |
| 2024-12-13 | Raman Prakash | Director | A-Award | A | Common Stock | 5,150 | 2.50 | 12.9K | 10,145 | D | ↗ |
| 2024-12-13 | Campbell Shannon | Director | A-Award | A | Common Stock | 4,500 | 2.50 | 11.3K | 8,865 | D | ↗ |
| 2024-12-13 | Behbahani Ali | Director | A-Award | A | Common Stock | 5,750 | 2.50 | 14.4K | 63,334 | D | ↗ |
| 2024-09-20 | Raman Prakash | Director | A-Award | A | Common Stock | 2,694 | 4.78 | 12.9K | 4,995 | D | ↗ |
| 2024-09-20 | Campbell Shannon | Director | A-Award | A | Common Stock | 2,354 | 4.78 | 11.3K | 4,365 | D | ↗ |
| 2024-09-20 | Behbahani Ali | Director | A-Award | A | Common Stock | 3,007 | 4.78 | 14.4K | 57,584 | D | ↗ |
| 2024-08-28 | Versant Venture Capital VI, L.P. | 10% Owner | S-Sale | D | Common Stock | 221,600 | 6.32 | 1.40M | 3,726,341 | — | ↗ |
| 2024-06-21 | Raman Prakash | Director | A-Award | A | Common Stock | 2,301 | 4.98 | 11.5K | 2,301 | — | ↗ |
| 2024-06-21 | Campbell Shannon | Director | A-Award | A | Common Stock | 2,011 | 4.98 | 10.0K | 2,011 | — | ↗ |
| 2024-06-21 | Behbahani Ali | Director | A-Award | A | Common Stock | 2,887 | 4.98 | 14.4K | 54,577 | — | ↗ |
| 2024-06-06 | Raman Prakash | Director | A-Award | A | Stock Option (Right to Buy) | 30,550 | 4.65 | 142.1K | 30,550 | — | ↗ |
| 2024-06-06 | Menzel Garry E | Director | A-Award | A | Stock Option (Right to Buy) | 30,550 | 4.65 | 142.1K | 30,550 | — | ↗ |
| 2024-06-06 | Kulkarni Samarth | Director | A-Award | A | Stock Option (Right to Buy) | 30,550 | 4.65 | 142.1K | 30,550 | — | ↗ |
| 2024-06-06 | Dhingra Kapil | Director | A-Award | A | Stock Option (Right to Buy) | 30,550 | 4.65 | 142.1K | 30,550 | — | ↗ |
| 2024-06-06 | Campbell Shannon | Director | A-Award | A | Stock Option (Right to Buy) | 30,550 | 4.65 | 142.1K | 30,550 | — | ↗ |
| 2024-06-06 | Behbahani Ali | Director | A-Award | A | Stock Option (Right to Buy) | 30,550 | 4.65 | 142.1K | 30,550 | — | ↗ |
| 2024-04-10 | Raman Prakash | Director | A-Award | A | Stock Option (Right to Buy) | 61,100 | 4.98 | 304.3K | 61,100 | — | ↗ |
| 2024-04-10 | Campbell Shannon | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-03-15 | DIXON WENDY L | Director | A-Award | A | Common Stock | 3,253 | 4.54 | 14.8K | 38,054 | — | ↗ |
| 2024-03-15 | Behbahani Ali | Director | A-Award | A | Common Stock | 3,166 | 4.54 | 14.4K | 51,690 | — | ↗ |
| 2024-02-14 | Yurasov Sergey | Officer | A-Award | A | Stock Option (Right to Buy) | 225,000 | 4.86 | 1.09M | 225,000 | — | ↗ |
| 2024-02-14 | Velleca Mark A. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 537,000 | 4.86 | 2.61M | 537,000 | — | ↗ |
| 2024-02-14 | Ni Fang | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 4.86 | 972.0K | 200,000 | — | ↗ |
| 2024-02-14 | Jones Erika | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 4.86 | 486.0K | 100,000 | — | ↗ |
| 2024-02-14 | Hatzis-Schoch Brent | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 4.86 | 972.0K | 200,000 | — | ↗ |
| 2024-02-14 | Buck Elizabeth | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 4.86 | 972.0K | 200,000 | — | ↗ |
| 2023-12-15 | DIXON WENDY L | Director | A-Award | A | Common Stock | 4,043 | 2.73 | 11.0K | 34,801 | — | ↗ |
| 2023-12-15 | Behbahani Ali | Director | A-Award | A | Common Stock | 4,455 | 2.73 | 12.2K | 48,524 | — | ↗ |
| 2023-10-17 | BIOTECH GROWTH N V | 10% Owner | P-Purchase | A | Common Stock | 400,000 | 2.34 | 934.1K | 8,517,839 | — | ↗ |
| 2023-09-17 | Velleca Mark A. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,000,000 | 3.55 | 3.55M | 1,000,000 | — | ↗ |
| 2023-09-15 | Velleca Mark A. | Director / Officer | A-Award | A | Common Stock | 5,208 | 3.60 | 18.7K | 46,522 | — | ↗ |
| 2023-09-15 | DIXON WENDY L | Director | A-Award | A | Common Stock | 2,986 | 3.60 | 10.7K | 30,758 | — | ↗ |
| 2023-09-15 | Behbahani Ali | Director | A-Award | A | Common Stock | 3,299 | 3.60 | 11.9K | 44,069 | — | ↗ |
| 2023-07-05 | RA CAPITAL MANAGEMENT, L.P. | Director | P-Purchase | A | Common Stock | 935,850 | 5.00 | 4.68M | 3,213,828 | — | ↗ |
| 2023-07-05 | Behbahani Ali | Director | P-Purchase | A | Common Stock | 1,000,000 | 5.00 | 5.00M | 4,448,757 | — | ↗ |
| 2023-06-30 | BIOTECH GROWTH N V | 10% Owner | P-Purchase | A | Common Stock | 1,000,000 | 5.00 | 5.00M | 8,117,839 | — | ↗ |
| 2023-06-27 | Epstein David M. | Director / Officer | S-Sale | D | Common Stock | 25,000 | 6.70 | 167.5K | 671,423 | — | ↗ |
| 2023-06-27 | BIOTECH GROWTH N V | 10% Owner | P-Purchase | A | Common Stock | 1,740,000 | 5.49 | 9.56M | 7,117,839 | — | ↗ |
| 2023-06-16 | Velleca Mark A. | Director | A-Award | A | Common Stock | 8,929 | 2.10 | 18.8K | 41,314 | — | ↗ |
| 2023-06-16 | DIXON WENDY L | Director | A-Award | A | Common Stock | 5,119 | 2.10 | 10.7K | 27,772 | — | ↗ |
| 2023-06-16 | Behbahani Ali | Director | A-Award | A | Common Stock | 5,655 | 2.10 | 11.9K | 40,770 | — | ↗ |
| 2023-05-16 | Velleca Mark A. | Director | A-Award | A | Stock Option (Right to Buy) | 16,500 | 1.82 | 30.0K | 16,500 | — | ↗ |
| 2023-05-16 | Shah Rajeev M. | Director | A-Award | A | Stock Option (Right to Buy) | 16,500 | 1.82 | 30.0K | 16,500 | — | ↗ |
| 2023-05-16 | Menzel Garry E | Director | A-Award | A | Stock Option (Right to Buy) | 16,500 | 1.82 | 30.0K | 16,500 | — | ↗ |
| 2023-05-16 | Mayweg Alexander | Director | A-Award | A | Stock Option (Right to Buy) | 16,500 | 1.82 | 30.0K | 16,500 | — | ↗ |
| 2023-05-16 | Kulkarni Samarth | Director | A-Award | A | Stock Option (Right to Buy) | 16,500 | 1.82 | 30.0K | 16,500 | — | ↗ |
| 2023-05-16 | Dhingra Kapil | Director | A-Award | A | Stock Option (Right to Buy) | 16,500 | 1.82 | 30.0K | 16,500 | — | ↗ |
| 2023-05-16 | DIXON WENDY L | Director | A-Award | A | Stock Option (Right to Buy) | 16,500 | 1.82 | 30.0K | 16,500 | — | ↗ |
| 2023-05-16 | Behbahani Ali | Director | A-Award | A | Stock Option (right to buy) | 16,500 | 1.82 | 30.0K | 16,500 | — | ↗ |
| 2023-03-16 | Velleca Mark A. | Director | A-Award | A | Common Stock | 11,228 | 1.67 | 18.8K | 32,385 | — | ↗ |
| 2023-03-16 | DIXON WENDY L | Director | A-Award | A | Common Stock | 6,437 | 1.67 | 10.7K | 22,653 | — | ↗ |
| 2023-03-16 | Behbahani Ali | Director | A-Award | A | Common Stock | 7,111 | 1.67 | 11.9K | 35,115 | — | ↗ |
| 2023-02-13 | Yurasov Sergey | Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 2.92 | 730.0K | 250,000 | — | ↗ |
| 2023-02-13 | Ni Fang | Officer | A-Award | A | Stock Option (Right to Buy) | 400,000 | 2.92 | 1.17M | 400,000 | — | ↗ |
| 2023-02-13 | Jones Erika | Officer | A-Award | A | Common Stock | 5,075 | 0.00 | — | 10,150 | — | ↗ |
| 2023-02-13 | Hatzis-Schoch Brent | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 2.92 | 584.0K | 200,000 | — | ↗ |
| 2023-02-13 | Epstein David M. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 420,000 | 2.92 | 1.23M | 420,000 | — | ↗ |
| 2023-02-13 | Buck Elizabeth | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 2.92 | 584.0K | 200,000 | — | ↗ |
| 2022-12-22 | Ni Fang | Director | P-Purchase | A | Common Stock | 36,363 | 1.28 | 46.6K | 125,389 | — | ↗ |
| 2022-12-21 | Ni Fang | Director | P-Purchase | A | Common Stock | 20,000 | 1.29 | 25.8K | 89,026 | — | ↗ |
| 2022-12-16 | Velleca Mark A. | Director | A-Award | A | Common Stock | 8,424 | 1.50 | 12.6K | 21,157 | — | ↗ |
| 2022-12-16 | INGRAM ROBERT ALEXANDER | Director | A-Award | A | Common Stock | 9,375 | 1.50 | 14.1K | 42,854 | — | ↗ |
| 2022-12-16 | DIXON WENDY L | Director | A-Award | A | Common Stock | 7,167 | 1.50 | 10.8K | 16,216 | — | ↗ |
| 2022-12-16 | Behbahani Ali | Director | A-Award | A | Common Stock | 7,917 | 1.50 | 11.9K | 28,004 | — | ↗ |
| 2022-10-31 | BIOTECH GROWTH N V | Director | P-Purchase | A | Common Stock | 99,801 | 2.25 | 224.9K | 5,377,839 | — | ↗ |
| 2022-10-28 | BIOTECH GROWTH N V | Director | P-Purchase | A | Common Stock | 172,974 | 2.18 | 377.0K | 5,278,038 | — | ↗ |
| 2022-10-27 | BIOTECH GROWTH N V | Director | P-Purchase | A | Common Stock | 191,678 | 1.87 | 359.2K | 5,105,064 | — | ↗ |
| 2022-10-21 | BIOTECH GROWTH N V | Director | P-Purchase | A | Common Stock | 87,850 | 1.51 | 132.8K | 4,913,386 | — | ↗ |
| 2022-10-20 | BIOTECH GROWTH N V | Director | P-Purchase | A | Common Stock | 53,734 | 1.42 | 76.3K | 4,825,536 | — | ↗ |
| 2022-10-19 | BIOTECH GROWTH N V | Director | P-Purchase | A | Common Stock | 77,689 | 1.32 | 102.8K | 4,771,802 | — | ↗ |
| 2022-09-16 | Velleca Mark A. | Director | A-Award | A | Common Stock | 4,294 | 2.62 | 11.3K | 12,733 | — | ↗ |
| 2022-09-16 | INGRAM ROBERT ALEXANDER | Director | A-Award | A | Common Stock | 6,584 | 2.62 | 17.3K | 33,479 | — | ↗ |
| 2022-09-16 | DIXON WENDY L | Director | A-Award | A | Common Stock | 4,103 | 2.62 | 10.7K | 9,049 | — | ↗ |
| 2022-09-16 | Behbahani Ali | Director | A-Award | A | Common Stock | 4,532 | 2.62 | 11.9K | 20,087 | — | ↗ |
| 2022-06-29 | Ni Fang | Director | P-Purchase | A | Common Stock | 25,000 | 2.44 | 61.0K | 69,026 | — | ↗ |
| 2022-06-17 | Velleca Mark A. | Director | A-Award | A | Common Stock | 5,542 | 2.03 | 11.3K | 8,439 | — | ↗ |
| 2022-06-17 | INGRAM ROBERT ALEXANDER | Director | A-Award | A | Common Stock | 8,498 | 2.03 | 17.3K | 26,895 | — | ↗ |
| 2022-06-17 | DIXON WENDY L | Director | A-Award | A | Common Stock | 4,060 | 2.03 | 8.2K | 4,060 | — | ↗ |
| 2022-06-17 | Behbahani Ali | Director | A-Award | A | Common Stock | 5,850 | 2.03 | 11.9K | 15,555 | — | ↗ |
| 2022-06-10 | Yurasov Sergey | Officer | — | D | Stock Option (Right to Buy) | 250,000 | 1.79 | 447.5K | 0 | — | ↗ |
| 2022-06-10 | Velleca Mark A. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-06-10 | Shah Rajeev M. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-06-10 | Menzel Garry E | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-06-10 | Mayweg Alexander | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-06-10 | Kulkarni Samarth | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-06-10 | INGRAM ROBERT ALEXANDER | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-06-10 | Dhingra Kapil | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-06-10 | DIXON WENDY L | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-06-10 | Behbahani Ali | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-04-28 | BIOTECH GROWTH N V | 10% Owner | P-Purchase | A | Common Stock | 255,711 | 2.57 | 657.9K | 4,694,113 | — | ↗ |
| 2022-04-27 | BIOTECH GROWTH N V | 10% Owner | P-Purchase | A | Common Stock | 150,000 | 2.66 | 399.5K | 4,438,402 | — | ↗ |
| 2022-04-27 | BB BIOTECH AG | Director | P-Purchase | A | Common Stock | 150,000 | 2.66 | 399.5K | 4,438,402 | — | ↗ |
| 2022-04-19 | BIOTECH GROWTH N V | 10% Owner | P-Purchase | A | Common Stock | 150,000 | 3.24 | 486.6K | 4,288,402 | — | ↗ |
| 2022-04-18 | BIOTECH GROWTH N V | 10% Owner | P-Purchase | A | Common Stock | 150,000 | 3.29 | 493.9K | 4,138,402 | — | ↗ |
| 2022-04-18 | BB BIOTECH AG | Director | P-Purchase | A | Common Stock | 150,000 | 3.29 | 493.9K | 4,138,402 | — | ↗ |
| 2022-04-13 | BIOTECH GROWTH N V | 10% Owner | P-Purchase | A | Common Stock | 102,556 | 3.57 | 366.2K | 3,988,402 | — | ↗ |
| 2022-04-12 | BIOTECH GROWTH N V | 10% Owner | P-Purchase | A | Common Stock | 150,000 | 3.42 | 513.6K | 3,885,846 | — | ↗ |
| 2022-04-12 | BB BIOTECH AG | Director | P-Purchase | A | Common Stock | 150,000 | 3.42 | 513.6K | 3,885,846 | — | ↗ |
| 2022-04-11 | BIOTECH GROWTH N V | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 3,735,846 | — | ↗ |
| 2022-04-06 | DIXON WENDY L | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 3.04 | 91.2K | 30,000 | — | ↗ |
| 2022-03-18 | Velleca Mark A. | Director | A-Award | A | Common Stock | 2,897 | 3.02 | 8.7K | 2,897 | — | ↗ |
| 2022-03-18 | INGRAM ROBERT ALEXANDER | Director | A-Award | A | Common Stock | 5,795 | 3.02 | 17.5K | 18,397 | — | ↗ |
| 2022-03-18 | Behbahani Ali | Director | A-Award | A | Common Stock | 4,346 | 3.02 | 13.1K | 9,705 | — | ↗ |
| 2022-02-15 | Ni Fang | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 3.79 | 379.0K | 100,000 | — | ↗ |
| 2022-02-15 | Jones Erika | Officer | A-Award | A | Stock Option (Right to Buy) | 20,300 | 3.79 | 76.9K | 20,300 | — | ↗ |
| 2022-02-15 | Hatzis-Schoch Brent | Officer | A-Award | A | Stock Option (Right to Buy) | 90,000 | 3.79 | 341.1K | 90,000 | — | ↗ |
| 2022-02-15 | Epstein David M. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 300,000 | 3.79 | 1.14M | 300,000 | — | ↗ |
| 2022-02-15 | Buck Elizabeth | Officer | A-Award | A | Stock Option (Right to Buy) | 90,000 | 3.79 | 341.1K | 90,000 | — | ↗ |
| 2021-12-17 | INGRAM ROBERT ALEXANDER | Director | A-Award | A | Common Stock | 3,296 | 5.31 | 17.5K | 12,602 | — | ↗ |
| 2021-12-17 | Behbahani Ali | Director | A-Award | A | Common Stock | 2,472 | 5.31 | 13.1K | 5,359 | — | ↗ |
| 2021-11-18 | Ni Fang | Officer | — | D | Stock Option (Right to Buy) | 55,000 | 28.69 | 1.58M | 0 | — | ↗ |
| 2021-11-18 | Jones Erika | Officer | — | D | Stock Option (Right to Buy) | 10,800 | 24.84 | 268.3K | 0 | — | ↗ |
| 2021-09-17 | INGRAM ROBERT ALEXANDER | Director | A-Award | A | Common Stock | 1,869 | 9.90 | 18.5K | 9,306 | — | ↗ |
| 2021-09-17 | Behbahani Ali | Director | A-Award | A | Common Stock | 1,326 | 9.90 | 13.1K | 2,887 | — | ↗ |
| 2021-09-15 | Buck Elizabeth | Officer | — | D | Common Stock | 0 | 0.00 | — | 95,192 | — | ↗ |
| 2021-08-09 | Velleca Mark A. | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 9.85 | 295.5K | 30,000 | — | ↗ |
| 2021-06-18 | Shah Rajeev M. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 12.55 | 188.3K | 15,000 | — | ↗ |
| 2021-06-18 | Menzel Garry E | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 12.55 | 188.3K | 15,000 | — | ↗ |
| 2021-06-18 | Mayweg Alexander | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 12.55 | 188.3K | 15,000 | — | ↗ |
| 2021-06-18 | Kulkarni Samarth | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 12.55 | 188.3K | 15,000 | — | ↗ |
| 2021-06-18 | INGRAM ROBERT ALEXANDER | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 12.55 | 188.3K | 15,000 | — | ↗ |
| 2021-06-18 | Dhingra Kapil | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 12.55 | 188.3K | 15,000 | — | ↗ |
| 2021-06-18 | Bolzon Bradley J PhD | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 15,000 | 12.55 | 188.3K | 15,000 | — | ↗ |
| 2021-06-18 | Behbahani Ali | Director | A-Award | A | Common Stock | 1,014 | 12.95 | 13.1K | 1,561 | — | ↗ |
| 2021-05-20 | Shah Rajeev M. | Director | J-Other | D | Common Stock | 443 | 24.01 | 10.6K | 0 | — | ↗ |
| 2021-05-12 | Hatzis-Schoch Brent | Officer | S-Sale | D | Common Stock | 1,161 | 26.11 | 30.3K | 11,317 | — | ↗ |
| 2021-05-03 | Roberts Christopher D. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,500 | 10.86 | 27.2K | 163,609 | — | ↗ |
| 2021-04-20 | Menzel Garry E | Director | A-Award | A | Stock Option (Right to Buy) | 14,921 | 24.33 | 363.0K | 14,921 | — | ↗ |
| 2021-04-20 | Kulkarni Samarth | Director | A-Award | A | Stock Option (Right to Buy) | 14,921 | 24.33 | 363.0K | 14,921 | — | ↗ |
| 2021-04-12 | Hatzis-Schoch Brent | Officer | M-Exempt | D | Stock Option (Right to Buy) | 179,915 | 3.20 | 575.7K | 164,552 | — | ↗ |
| 2021-04-05 | Roberts Christopher D. | Officer | S-Sale | D | Common Stock | 2,500 | 25.54 | 63.8K | 3,200 | — | ↗ |
| 2021-04-01 | Shah Rajeev M. | Director | J-Other | A | Common Stock | 353,814 | 24.26 | 8.58M | 2,277,978 | — | ↗ |
| 2021-03-18 | Shah Rajeev M. | Director | A-Award | A | Common Stock | 443 | 24.01 | 10.6K | 443 | — | ↗ |
| 2021-03-18 | INGRAM ROBERT ALEXANDER | Director | A-Award | A | Common Stock | 677 | 24.01 | 16.3K | 6,182 | — | ↗ |
| 2021-03-18 | Behbahani Ali | Director | A-Award | A | Common Stock | 547 | 24.01 | 13.1K | 547 | — | ↗ |
| 2021-03-12 | Hatzis-Schoch Brent | Officer | M-Exempt | D | Stock Option (Right to Buy) | 4,078 | 3.20 | 13.0K | 168,630 | — | ↗ |
| 2021-03-03 | Roberts Christopher D. | Officer | S-Sale | D | Common Stock | 884 | 26.57 | 23.5K | 3,200 | — | ↗ |
| 2021-02-17 | Roberts Christopher D. | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 28.69 | 2.15M | 75,000 | — | ↗ |
| 2021-02-17 | Leggett Thomas | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 28.69 | 2.15M | 75,000 | — | ↗ |
| 2021-02-17 | Hatzis-Schoch Brent | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 28.69 | 2.15M | 75,000 | — | ↗ |
| 2021-02-17 | HUMPHREY RACHEL | Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 28.69 | 1.72M | 60,000 | — | ↗ |
| 2021-02-17 | Epstein David M. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 225,000 | 28.69 | 6.46M | 225,000 | — | ↗ |
| 2021-02-12 | Hatzis-Schoch Brent | Officer | M-Exempt | D | Stock Option (Right to Buy) | 4,078 | 3.20 | 13.0K | 172,708 | — | ↗ |
| 2021-02-03 | Roberts Christopher D. | Officer | M-Exempt | A | Common Stock | 2,500 | 10.86 | 27.2K | 5,700 | — | ↗ |
| 2021-01-19 | Dhingra Kapil | Director | — | D | Common Stock | 0 | 0.00 | — | 10,000 | — | ↗ |
| 2021-01-12 | Hatzis-Schoch Brent | Officer | S-Sale | D | Common Stock | 1,669 | 30.50 | 50.9K | 16,261 | — | ↗ |
| 2021-01-08 | Leggett Thomas | Officer | M-Exempt | D | Stock Option (Right to Buy) | 3,000 | 10.86 | 32.6K | 218,171 | — | ↗ |
| 2021-01-04 | Roberts Christopher D. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,500 | 10.86 | 27.2K | 173,609 | — | ↗ |
| 2021-01-04 | Epstein David M. | Director / Officer | M-Exempt | A | Common Stock | 3,000 | 6.42 | 19.3K | 708,423 | — | ↗ |
| 2020-12-28 | Hatzis-Schoch Brent | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,400 | 3.20 | 17.3K | 180,864 | — | ↗ |
| 2020-12-15 | Roberts Christopher D. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 3,200 | 10.86 | 34.8K | 176,109 | — | ↗ |
| 2020-12-15 | INGRAM ROBERT ALEXANDER | Director | A-Award | A | Common Stock | 505 | 34.29 | 17.3K | 5,505 | — | ↗ |
| 2020-12-15 | Epstein David M. | Director / Officer | M-Exempt | A | Common Stock | 2,500 | 6.42 | 16.1K | 705,423 | — | ↗ |
| 2020-12-14 | Versant Venture Capital VI, L.P. | 10% Owner | J-Other | D | Common Stock | 307 | 0.00 | — | 0 | — | ↗ |
| 2020-12-14 | Hatzis-Schoch Brent | Officer | S-Sale | D | Common Stock | 4,078 | 34.95 | 142.5K | 3,000 | — | ↗ |
| 2020-12-14 | Bolzon Bradley J PhD | Director / 10% Owner | J-Other | D | Common Stock | 20,784 | 0.00 | — | 822,140 | — | ↗ |
| 2020-12-08 | Leggett Thomas | Officer | M-Exempt | A | Common Stock | 3,000 | 10.86 | 32.6K | 3,000 | — | ↗ |
| 2020-12-03 | Roberts Christopher D. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,500 | 10.86 | 27.2K | 179,309 | — | ↗ |
| 2020-12-01 | Epstein David M. | Officer | S-Sale | D | Common Stock | 10,923 | 32.64 | 356.6K | 704,000 | — | ↗ |
| 2020-11-30 | Versant Venture Capital VI, L.P. | 10% Owner | J-Other | D | Common Stock | 463 | 0.00 | — | 0 | — | ↗ |
| 2020-11-30 | Bolzon Bradley J PhD | Director / 10% Owner | J-Other | A | Common Stock | 467 | 0.00 | — | 467 | — | ↗ |
| 2020-11-27 | Versant Venture Capital VI, L.P. | 10% Owner | J-Other | A | Common Stock | 7,880 | 0.00 | — | 7,880 | — | ↗ |
| 2020-11-27 | Bolzon Bradley J PhD | Director / 10% Owner | J-Other | A | Common Stock | 6,797 | 0.00 | — | 6,797 | — | ↗ |
| 2020-11-23 | Versant Venture Capital VI, L.P. | 10% Owner | J-Other | A | Common Stock | 8,223 | 0.00 | — | 8,223 | — | ↗ |
| 2020-11-23 | Bolzon Bradley J PhD | Director / 10% Owner | J-Other | D | Common Stock | 154,671 | 0.00 | — | 1,277,541 | — | ↗ |
| 2020-11-19 | Versant Venture Capital VI, L.P. | 10% Owner | S-Sale | D | Common Stock | 114,854 | 33.01 | 3.79M | 4,818,600 | — | ↗ |
| 2020-11-19 | Bolzon Bradley J PhD | Director / 10% Owner | S-Sale | D | Common Stock | 114,854 | 33.01 | 3.79M | 4,818,600 | — | ↗ |
| 2020-11-18 | Versant Venture Capital VI, L.P. | 10% Owner | S-Sale | D | Common Stock | 473 | 33.09 | 15.7K | 4,933,454 | — | ↗ |
| 2020-11-18 | Bolzon Bradley J PhD | Director / 10% Owner | S-Sale | D | Common Stock | 473 | 33.09 | 15.7K | 4,933,454 | — | ↗ |
| 2020-11-17 | Versant Venture Capital VI, L.P. | 10% Owner | S-Sale | D | Common Stock | 489 | 33.05 | 16.2K | 984,180 | — | ↗ |
| 2020-11-17 | Bolzon Bradley J PhD | Director / 10% Owner | S-Sale | D | Common Stock | 3,705 | 33.05 | 122.4K | 4,933,927 | — | ↗ |
| 2020-11-16 | Versant Venture Capital VI, L.P. | 10% Owner | S-Sale | D | Common Stock | 23 | 33.01 | 759.29 | 984,669 | — | ↗ |
| 2020-11-16 | Bolzon Bradley J PhD | Director / 10% Owner | S-Sale | D | Common Stock | 23 | 33.01 | 759.29 | 984,669 | — | ↗ |
Executive team
Top executives
EBIT / Employee
827.9K
Shares Outstanding
57.30M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Mark A. Velleca, M.D., Ph.D. President and Chief Executive Officer | 667.4K | — | 189.0K | 1.01M | 348.7K | 23.8K | 2.23M | 53.47% | ↗ |
| 2 | 2025 | Sergey Yurasov, M.D., Ph.D. Chief Medical Officer | 525.6K | — | 189.0K | 402.3K | 212.3K | 22.8K | 1.35M | 43.74% | ↗ |
| 3 | 2025 | Brent Hatzis-Schoch, Esq. Chief Operating Officer and General Counsel | 511.0K | — | 189.0K | 352.0K | 206.4K | 23.8K | 1.28M | 42.19% | ↗ |
| 4 | 2024 | Mark A. Velleca, M.D., Ph.D. President and Chief Executive Officer | 644.8K | — | — | 1.88M | 319.2K | 8.9K | 2.86M | 65.93% | ↗ |
| 5 | 2024 | Sergey Yurasov, M.D., Ph.D. Chief Medical Officer | 507.8K | — | — | 788.9K | 197.0K | 21.1K | 1.51M | 52.08% | ↗ |
| 6 | 2024 | Brent Hatzis-Schoch, Esq. Chief Operating Officer and General Counsel | 493.7K | — | — | 701.4K | 191.6K | 18.5K | 1.41M | 49.92% | ↗ |
| 7 | 2024 | Brent Hatzis-Schoch, Esq. Chief Operating Officer and General Counsel | 493.7K | — | — | 701.4K | 191.6K | 18.5K | 1.41M | 49.92% | ↗ |
| 8 | 2023 | Mark A. Velleca, M.D., Ph.D. President and Chief Executive Officer | 180.3K | — | — | 2.59M | 113.7K | 64.0K | 2.95M | 87.85% | ↗ |
| 9 | 2023 | Mark A. Velleca, M.D., Ph.D. President and Chief Executive Officer | 180.8K | — | — | 2.59M | 113.7K | 64.0K | 2.95M | 87.85% | ↗ |
| 10 | 2023 | David M. Epstein, Ph.D. Former President and Chief Executive Officer | 412.3K | — | — | 1.05M | — | 557.4K | 2.02M | 51.98% | ↗ |
| 11 | 2023 | Fang Ni, Pharm.D. Chief Business Officer and Interim Chief Financial Officer | 450.9K | — | — | 823.5K | 189.4K | 25.8K | 1.49M | 55.29% | ↗ |
| 12 | 2023 | Sergey Yurasov, M.D., Ph.D. Chief Medical Officer | 488.3K | — | — | 514.8K | 205.1K | 25.6K | 1.23M | 41.73% | ↗ |
| 13 | 2022 | David M. Epstein, Ph.D. Former President and Chief Executive Officer | 554.4K | — | — | 759.8K | 310.4K | 20.3K | 1.64M | 46.19% | ↗ |
| 14 | 2022 | David M. Epstein, Ph.D. President and Chief Executive Officer | 554.4K | — | — | 759.8K | 310.4K | 20.3K | 1.64M | 46.19% | ↗ |
| 15 | 2022 | Brent Hatzis-Schoch Chief Operating Officer, General Counsel | 452.1K | — | — | 227.9K | 207.7K | 23.5K | 911.2K | 25.01% | ↗ |
| 16 | 2022 | Fang Ni, Pharm.D. Chief Business Officer and Interim Chief Financial Officer | 411.7K | — | — | 253.4K | 197.0K | 47.6K | 909.8K | 27.86% | ↗ |
| 17 | 2022 | Fang Ni, Pharm.D. Chief Business Officer and Chief Financial Officer | 411.7K | — | — | 253.4K | 197.0K | 47.6K | 909.8K | 27.86% | ↗ |
| 18 | 2021 | David M. Epstein, Ph.D. President and Chief Executive Officer | 538.2K | — | — | 4.24M | 228.7K | 87.8K | 5.09M | 83.21% | ↗ |
| 19 | 2021 | Brent Hatzis-Schoch Chief Operating Officer, General Counsel | 438.9K | — | — | 1.41M | 149.2K | 22.4K | 2.02M | 69.81% | ↗ |
| 20 | 2021 | Thomas Leggett Former Chief Financial Officer | 381.9K | — | — | 1.41M | — | 62.5K | 1.86M | 76.06% | ↗ |
| 21 | 2021 | Fang Ni, Pharm.D. Chief Business Officer and Chief Financial Officer | 388.1K | 25.0K | — | 1.04M | 132.0K | 94.2K | 1.67M | 61.83% | ↗ |
| 22 | 2021 | Fang Ni, Pharm.D. Chief Business Officer and Interim Chief Financial Officer | 388.1K | 25.0K | — | 1.04M | 132.0K | 94.2K | 1.67M | 61.83% | ↗ |
| 23 | 2020 | David M. Epstein, Ph.D. President and Chief Executive Officer | 507.8K | — | — | 3.03M | 270.4K | 59.6K | 3.87M | 78.34% | ↗ |
| 24 | 2020 | Rachel Humphrey, M.D. Chief Medical Officer | 144.6K | 25.0K | 281.4K | 2.47M | 49.0K | 10.3K | 2.98M | 92.32% | ↗ |
| 25 | 2020 | Brent Hatzis-Schoch Chief Operating Officer, General Counsel | 418.3K | 50.0K | — | 856.8K | 184.8K | 17.1K | 1.53M | 56.11% | ↗ |
| 26 | 2019 | David M. Epstein, Ph.D. President and Chief Executive Officer | 428.9K | — | — | 2.73M | 171.6K | 16.8K | 3.35M | 81.55% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mark A. Velleca | Chief Executive Officer, President & Chairman | 1M | — |
| Sergey Yurasov | Chief Medical Officer | 760.7K | — |
| Brent Hatzis-Schoch | Chief Operating Officer & General Counsel | 741.2K | male |
| Elizabeth Buck | Co-Founder & Chief Scientific Officer | 340.5K | — |
| Erika Jones | Principal Financial Officer, Principal Accounting Officer, SVP of Finance & Corporate Controller | — | female |
| Melanie Morrison | Chief Development Officer | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BDTX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
